GSK presents positive data on Breo/Relvar Ellipta for COPD

UK pharma major GlaxoSmithKline (LSE: GSK) and US partner Innoviva (Nasdaq: INVA) have presented positive new data on their Breo Ellipta (fluticasone furoate/vilanterol or FF/VI 100/25mcg) for chronic obstructive pulmonary disease (COPD).

The data, which was presented at the American Thoracic Society (ATS) Conference, is from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial, which failed to meet its primary endpoint.

One analysis demonstrated that patients with COPD and moderate airflow limitation receiving Breo Ellipta achieved improvements in exacerbations compared with placebo.